Tough month for APLS
• 1st: safety issue surfaces for SYFOVRE
⇨ Retinal Vasculitis
• Now: IZERVAY approved early
⇨ Good for AMD patients to have 2 options
Dosing differences favor SYFOVRE
• SYFOVRE once every 25-60 days
• IZERVAY once monthly
Eye injections
So maybe dosing difference is important?
SYFOVRE safety issue
will be front and center
• Rare issue that seems stable
⇨ Maybe will become minor issue?
⇨ Doesn't appear to be related to MOA
Will a similar safety issue appear for IZERVAY?
SYFOVRE (APLS) vs. IZERVAY (Astellas)
Interesting technology differences
Similar MOA
inhibiting complement /
decreasing MAC formation
SYFOVRE thru C3
IZERVAY thru C5
SYFOVRE - pegcetacoplan
peptide - PEG (40kDa) - peptide
IZERVAY - avacincaptad pegol sodium
RNA aptamer - PEG (43kDa)
How does their efficacy compare?
• Efficacy from pkg insert
⇨ Month 12 vs. [control]
SYFOVRE (monthly)
⇨ 1.75 vs. [1.97]
SYFOVRE (every other month)
⇨ 1.73 vs. [1.97]
IZERVAY (monthly) (GATHER1)
⇨ 1.22 vs. [1.89]
IZERVAY (monthly) (GATHER2)
⇨ 1.75 vs. [2.12]
This article is NOT legal, investment or tax advice. Please do your own diligence before making any investment decisions.
Article History: Originally posted 8/7/23 (RB)